Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages

Posted by on Jul 1st, 2026

Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has earned a consensus recommendation of “Buy” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $47.5714.

A number of equities research analysts have commented on IMUX shares. Guggenheim started coverage on Immunic in a report on Tuesday, March 24th. They set a “buy” rating and a $70.00 target price on the stock. Roth Mkm reiterated a “buy” rating and set a $19.00 target price on shares of Immunic in a report on Thursday, May 14th. D. Boral Capital cut Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. Wolfe Research started coverage on Immunic in a report on Friday, May 22nd. They set an “outperform” rating on the stock. Finally, Wall Street Zen cut Immunic from a “hold” rating to a “sell” rating in a report on Sunday, April 19th.

View Our Latest Analysis on Immunic

Institutional Investors Weigh In On Immunic

Large investors have recently bought and sold shares of the stock. OMERS ADMINISTRATION Corp acquired a new stake in Immunic during the 1st quarter valued at $187,000. Renaissance Technologies LLC purchased a new position in shares of Immunic during the 1st quarter worth $1,020,000. XTX Topco Ltd purchased a new position in shares of Immunic during the 4th quarter worth $120,000. Jane Street Group LLC lifted its stake in shares of Immunic by 46.8% during the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock worth $153,000 after purchasing an additional 91,346 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Immunic during the 3rd quarter worth $29,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Price Performance

NASDAQ IMUX opened at $15.37 on Wednesday. Immunic has a 1-year low of $5.06 and a 1-year high of $15.84. The company has a market capitalization of $209.34 million, a P/E ratio of -2.75 and a beta of 1.37. The business has a 50 day moving average price of $12.67 and a 200 day moving average price of $10.12.

Immunic (NASDAQ:IMUX – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.37). On average, research analysts expect that Immunic will post -4.57 earnings per share for the current fiscal year.

Immunic Company Profile

(Get Free Report)

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.

Featured Stories

Analyst Recommendations for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.